

Original Article**Evaluation of Polymyxin B Susceptibility Profile and Detection of Drug Resistance Genes among *Acinetobacter Baumannii* Clinical Isolates in Tehran, Iran during 2015-2016**Reza Mirnejad¹, Mohsen Heidary^{2*}, Aghil Bahramian³, Mehdi Goudarzi³ and Abazar Pournajaf⁴.¹ Molecular Biology Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.² Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.³ Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.⁴ Department of Microbiology, Faculty of Medicine, Babol University of medical sciences, Babol, Iran.**Competing interests:** The authors have declared that no competing interests exist.

Abstract. *Acinetobacter baumannii* is an important opportunistic pathogen, responsible for approximately 10% of all gram-negative nosocomial infection. The aim of this study was to determine aminoglycoside and quinolone resistance genes and their antimicrobial susceptibility profile in the clinically *A. baumannii*. In this cross-sectional study, a total of 100 nonduplicative *A. baumannii* isolates were collected from different clinical samples. Antimicrobial susceptibility test was performed by disk diffusion method. *QnrA*, *anrB*, *qnrS*, *aac(3)-IIa*, and *aac(6')-Ib* genes were identified using PCR method. The results of antibiotic susceptibility test showed that polymyxin B was the most effective antimicrobial against *A. baumannii*. 97%, 95% and 82% of isolates were resistant to cefepime, ceftriaxone, and amikacin, respectively. The molecular distribution of *aac(3)-IIa*, *aac(6')-Ib*, and *qnrA* genes were 45%, 50%, and 50% of isolates, respectively. However, *qnrB* and *qnrS* genes could not be detected in any strain. This study showed that polymyxin B was the best drug against *A. baumannii* clinical isolates. This data is also valid for polymyxin E (colistin), which is mostly used in clinics. There is a high level of resistance genes among clinical *A. baumannii* isolates. This high prevalence rate highlights the necessity for the development of rapid diagnostic assays and continuous monitoring of antibiotic resistance.

Keywords: *Acinetobacter baumannii*, Aminoglycoside, Quinolone, Iran.**Citation:** Mirnejad R., Heidary M., Bahramian A., Goudarzi M., Pournajaf A. Evaluation of polymyxin b susceptibility profile and detection of drug resistance genes among *Acinetobacter baumannii* clinical isolates in tehran, iran during 2015-2016. *Mediterr J Hematol Infect Dis* 2018, 10(1): e2018044, DOI: <http://dx.doi.org/10.4084/MJHID.2018.044>**Published:** July 1, 2018**Received:** March 26, 2018**Accepted:** May 15, 2018This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Correspondence to: Mohsen Heidary, Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. E-mail: mohsenheidary40@gmail.com

Introduction. *Acinetobacter baumannii* is a lactose non-fermenting gram-negative bacillus (NF-GNB) that has emerged as a highly troublesome pathogen particularly in critically ill patients.¹ Clinical isolates of *A. baumannii* are responsible for pulmonary, device-related,

bloodstream, and urinary tract infections and are frequently isolated from hospitalized ICU patients.² These isolates were associated with multiple antibiotic resistance, and the spread of drug-resistant *A. baumannii* strains among hospitalized patients have become an increasing

public health threat.^{3,4} Furthermore, due to the intrinsic resistance mechanisms in this opportunistic nosocomial pathogen, it is quicker to become multidrug-resistant (MDR).⁵

Polymyxin B and polymyxin E (colistin), are an increasingly significant part of the antimicrobial agents against MDR gram-negative bacteria. These two drugs have the same spectrum and are appropriate for use in the clinical settings.^{6,7} At present in Europe in the patients with MDR *A. baumannii* the clinician utilize the colistin, and in the future, it is possible using the new derivatives.⁸

Aminoglycosides are used most commonly in the treatment of life-threatening infections caused by *A. baumannii* strains.⁹ The efflux pumps, decreased outer membrane permeability, amino acid substitutions and enzymatic modification, are the main mechanisms of aminoglycoside resistance in these bacteria.¹⁰ Enzymatic modification is the most common type of aminoglycoside resistance in *A. baumannii* clinical isolates and usually results in high-level drug resistance.¹¹ Most enzyme-mediated resistance in *A. baumannii* is due to the genes encoding for aminoglycoside-modifying enzymes (AMEs) which found on plasmids and transposons. Three types of AMEs include N-acetyltransferases (AAC), O-adenyltransferases (ANT), and O-phosphotransferases (APH).^{12,13}

The plasmid-mediated quinolone resistance (PMQR) genes, such as *qnrA*, *qnrB*, and *qnrS*, are responsible for quinolone resistance in *A. baumannii* isolates. PMQRs were first detected in the 1990s as a plasmid gene in *Klebsiella pneumoniae* clinical isolates. Subsequent studies have shown that *qnr* genes have a worldwide distribution in a range of Gram-negative opportunist pathogens. Although the *qnr* expression mechanism which confers clinical quinolone resistance is the least understood, the DNA topoisomerase protection protein Qnr protects DNA from quinolone binding and causes resistance to quinolones.¹⁴⁻¹⁶ The prevalence of quinolone- and/or aminoglycoside-resistant *A. baumannii* was increased during the past decade. The present study was carried out to investigate antibiotic resistance pattern and resistance-related genes such as *qnrA*, *qnrB*, *qnrS*, *aac(3)-IIa*, and *aac(6')-Ib* in *A. baumannii* clinical isolates by polymerase chain reaction (PCR) assay.

Materials and Methods. The current study was a cross-sectional descriptive research which conducted from February 2015 to April 2016, at two teaching hospitals (Baqiyatallah and Moheb mehr hospitals) in Tehran, Iran. One hundred non-repetitive strains of *A. baumannii* were obtained from different clinical specimens, including tracheal secretion, blood, wound, urine, and other samples. The isolates were identified using well-recognized biochemical tests such as Gram staining, oxidative/fermentative glucose test, catalase test, motility, oxidase test, citrate utilization, and capability to grow at 42–44°C.¹⁷ Species identification was confirmed by detection of *blaOXA-51-like* genes, as described previously.¹⁸ All strains were preserved in Luria-Bertani broth (Merck Co., Germany) containing 20% glycerol (v/v) at –80°C for further use.

Antimicrobial susceptibility was carried out on the Mueller-Hinton agar plates (Merck Co., Germany) using the Kirby-Bauer (KB) method as suggested by the Clinical and Laboratory Standards Institute guideline (CLSI document M100-S14).

The antimicrobial agents were as follows: meropenem (10 µg), gentamicin (10 µg), amikacin (30 µg), imipenem (10 µg), tobramycin (10 µg), tetracycline (30 µg), piperacillin-tazobactam (100-10 µg), cefepime (30 µg), ceftriaxone (30 µg), ampicillin-sulbactam (10-10 µg), and polymyxin B (300 µg) (MAST Diagnostics, Merseyside, UK). Multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) isolates were detected according to the instruction suggested by the Centers for Disease Control and Prevention (CDC). *Escherichia coli* ATCC 25922 and *Acinetobacter baumannii* ATCC 19606 were used as negative and positive controls, respectively.

Genomic DNA was extracted from *A. baumannii* colonies grown overnight on blood agar by Bioneer Co., Korea Kit and used as a template for PCR assay. PCR amplification was done to detect aminoglycoside-(*aac(3)-IIa* and *aac(6')-Ib*) and quinolone-(*qnrA*, *qnrB*, and *qnrS*) related resistance genes. Amplification of AME and PMQR genes was carried out using a thermal gradient cycler (Eppendorf Co., Germany) with the following protocol: 5 minutes at 94° C for the initial denaturation and 36 cycles of amplification consisting of 45 seconds at 94°C, 45 seconds at 52–58°C, and 45 seconds at 72°C, with 5 minutes

Table 1. PCR primers and annealing temperatures used in this study.

Target genes	Forward	Reverse	Annealing (°C)	Amplicon size (bp)
<i>qnrA</i>	ATTTCTCACGCCAGGATTTG	GATCGGCAAAGGTTAGGTCA	58	649
<i>qnrB</i>	GGCTCGAAATTCGCCACTG	TTTGCTGTTCCAGTCGAA	52	469
<i>qnrS</i>	GCA AGTTCATTGAACAGGGT	TCTAAACCGTCGAGTTCGGCG	50	428
<i>aac(3)-IIa</i>	CGGAAGGCAATAACGGAG	TCGAACAGGTAGCACTGAG	58	740
<i>aac(6)-Ib</i>	TTGCGATGCTCTATGAGTGGCTA	CTCGAATGCCTGGCGTGTT	55	611

at 72°C for the final extension. The specific primers, temperatures of annealing, and amplicons size used for PCR are detailed in **Table 1**.

The current survey was a descriptive research. The MINITAB16 software was used for statistical analyses. The P value and confidence intervals were ≤0.05 and 95%, respectively.

Results. One hundred isolates of *A. baumannii* were obtained from different clinical specimens. The samples included blood (n=40, 40%), tracheal secretion (n=27, 27%), wound (n=12, 12%), urine (n=8, 8%), and unknown (n=13, 13%) specimens isolated from hospitalized patients in ICU (n=40, 40%), emergency department (n=20, 20%), and infectious disease department (30, 30%), and other departments (n=10, 10%).

The resistance percentage of meropenem, gentamicin, amikacin, imipenem, tobramycin, tetracycline, piperacillin-tazobactam, cefepime, ceftriaxone, ampicillin-sulbactam and polymyxin B were 69%, 82%, 63%, 74%, 56%, 51%, 70%, 97%, 95%, 49%, 3%, respectively (**Table 2**).

Antibiotic susceptibility tests using the Kirby-Bauer method showed that the level of resistance to meropenem, gentamicin, amikacin, imipenem,

tobramycin, tetracycline, piperacillin-tazobactam, cefepime, ceftriaxone, ampicillin-sulbactam and polymyxin B was 69%, 82%, 63%, 74%, 56%, 51%, 70%, 97%, 95%, 49%, 3% (**Table 2**).

All 100 isolates of the main outbreak strains of *A. baumannii* were PCR positive for *blaOXA-51-like* genes.

Molecular distribution of aminoglycoside

Table 2. Antibiotics resistance profile among *A. baumannii* isolates.

Antibiotic	Resistant No (%)	Intermediate No (%)	Sensitive No (%)
Meropenem	69(69%)	16(16%)	15(15%)
Gentamicin	82(80.4%)	6(5.9%)	14(13.7%)
Amikacin	63(63%)	10(10%)	27(27%)
Imipenem	74(76%)	14(14%)	10(10%)
Tobramycin	56(56%)	7(7%)	37(37%)
Tetracycline	51(51%)	14(14%)	35(35%)
Piperacillin-Tazobactam	70(70%)	0(0%)	30(30%)
Cefepime	97(97%)	1(1%)	2(2%)
Ceftriaxone	95(95%)	5(5%)	0 (0%)
Ampicillin-Sulbactam	49(49%)	17(17%)	34(34%)
Polymyxin B	3(3%)	(0%)	97(97%)




Figure 1. **A)** PCR amplification of the *aac(3)-IIa* gene. Lane M: Ladder (100 bp), lane Cont-: negative control, lane Cont+: positive control (740bp); lane 1, 6, and 7: negative results and lane 2, 3, 4, and 5: positive results. **B)** PCR amplification of the *aac(6)-Ib* gene. Lane M: Ladder (100 bp), lane Cont-: negative control, lane Cont+: positive control (482bp); lane 1-7: positive results. **C)** PCR amplification of the *qnrA* gene. Lane M: Ladder (100 bp), lane Cont-: negative control, lane Cont+: positive control (649bp); lane 1-4, 5, and 7: positive results, lane 5: negative result.

resistance genes including *aac(3)-IIa* and *aac(6')-Ib* were 45% and 50%, respectively is shown in the **figure 1 A and B**. Half of the isolates (50%) contained the *qnrA* (**Figure 1C**). *QnrB* and *qnrS* were not found in any strains. Sequencing of PCR products for AME and PMQR genes were confirmed by BLAST at NCBI.

Discussion. Drug resistance in *A. baumannii* has become a global problem for the severely infected patients who critically rely on Antimicrobial therapy. The emergence of clinical *A. baumannii* strains with different antibiotic resistance phenotypes causes difficulties in treating infections caused by this organism.^{19,20}

Multidrug-resistant *A. baumannii* (MDR-Ab) is a subject of profound anxiety as it not only causes severe and fatal infections but also increases the length of hospital stay, resulting in augmented treatment charges.²¹

In this study, the most antibiotic resistance in *A. baumannii* isolates were related to cefepime (97%), ceftriaxone (95%), and amikacin (82%), and the most effective drug against these isolates was polymyxin B. This data is also valid for colistin, which is mostly used in clinics worldwide.

Henwood et al.,²² showed that more than 75% of *A.baumannii* strains were resistant to cefotaxime and ceftazidime. In another study, Karlowsky et al.,²³ showed that >90% of *A. baumannii* isolates were susceptible to imipenem and meropenem; fewer strains were susceptible to amikacin, and <60% were susceptible to ceftazidime and gentamicin.

In agreement with the current study, polymyxins, are active agents against the overwhelming majority of *A. baumannii* throughout the world. In a systematic review study directed by Razavi Nikoo et al.,²⁴ polymyxins presented adequate activity against *A. baumannii* collected. The frequencies of MDR and XDR

isolates were 70% and 19% respectively. No PDR isolates were identified in this study.

Hujer et al.²⁵ in their study reported that 89% of *A. baumannii* were resistant to at least three different classes of antibiotics, and 15% were resistant to all antibiotics tested.

Aminoglycosides are used most commonly in the treatment of *A. baumannii* infections. Most enzyme-mediated resistance in *A. baumannii* is due to AMEs encoded genes which found on the mobile genetic elements.

PMQR genes including *qnrA*, *qnrB*, and *qnrS* are responsible for quinolone resistance in *A. baumannii* which the prevalence of quinolone-resistant *A. baumannii* was increased in recent years. In our study, the prevalence rate of PMQR genes including *qnrA*, *qnrB*, and *qnrS* was 50%, 0%, and 0%, respectively. In contrast with our data, Chagas et al.,²⁶ showed that the prevalence of *qnrA* gene was 37.5% (n=15). The differences mentioned above can result from the geographical distance, surveillance strategies, and restraint in antibiotic prescriptions in other regions.

Conclusions. This study showed that the most effective antibiotic against clinical strains of *A. baumannii* was polymyxin B and we recommend clinicians to use polymyxins (B or E) in patients infected with MDR *A. baumannii*. However, overusing can lead to polymyxin resistance, and the drug's toxicity problems should be considered. There is a high level of aminoglycoside resistance genes among *A. baumannii* isolates circulating in hospitals in Iran. This trend of MDR profiles associated with the presence of *aac(6')-Ib* and *aac(3)-IIa* genes are worrying. The high prevalence rate of these resistance genes highlights the necessity for establishing more rapid diagnostic assays, more antimicrobial susceptibility tests, more clinician-laboratory correlation, and continuous monitoring of antibiotic resistance due to *A. baumannii*.

References:

1. Juyal D, Prakash R, Shanakamarayan SA, Sharma M, Negi V, Sharma N. Prevalence of non-fermenting gram negative bacilli and their in vitro susceptibility pattern in a tertiary care hospital of Uttarakhand: A study from foothills of Himalayas. Prevalence. 2013;2(2):108-12. <https://doi.org/10.4103/2278-0521.117915>
2. Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features. Saudi Journal of Biological Sciences. 2016.
3. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nature Reviews Microbiology. 2007;5(12):939. <https://doi.org/10.1038/nrmicro1789> PMID:18007677
4. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. Journal of Clinical Microbiology. 2006;44(8):2974-6. <https://doi.org/10.1128/JCM.01021-06> PMID:16891520 PMID:PMC1594603
5. Gholami M, Haghshenas M, Moshiri M, Razavi S, Pournajaf A, Irajian G, et al. Frequency of 16S rRNA Methylase and Aminoglycoside-Modifying Enzyme Genes among Clinical Isolates of Acinetobacter baumannii in Iran. Iranian Journal of Pathology.

- 2017;12(4):329.
6. Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. Expert review of anti-infective therapy. 2015;13(12):1481-97. <https://doi.org/10.1586/14787210.2015.1093933> PMID:26488563
 7. Kassamali Z, Danziger L. To B or not to B, that is the question: is it time to replace colistin with polymyxin B? Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015;35(1):17-21. <https://doi.org/10.1002/phar.1510> PMID:25346395
 8. Vaara M. New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin. Medicinal Research Reviews. 2018. <https://doi.org/10.1002/med.21494> PMID:29485690
 9. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant *Acinetobacter baumannii* infections. Drugs. 2014;74(12):1315-33. <https://doi.org/10.1007/s40265-014-0267-8> PMID:25091170 PMCid:PMC4258832
 10. Potron A, Poiriel L, Nordmann P. Emerging broad-spectrum resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: mechanisms and epidemiology. International journal of antimicrobial agents. 2015;45(6):568-85. <https://doi.org/10.1016/j.ijantimicag.2015.03.001> PMID:25857949
 11. Kashfi M, Hashemi A, Eslami G, Amin MS, Tarashi S, Taki E. The Prevalence of Aminoglycoside-Modifying Enzyme Genes Among *Pseudomonas aeruginosa* Strains Isolated From Burn Patients. Archives of Clinical Infectious Diseases. 2017;12(1).
 12. Huang L, Sun L, Yan Y. Time to positivity of blood culture is predictive for nosocomial infection and infectious endocarditis instead of other clinical characteristics and prognosis in *Acinetobacter baumannii* bloodstream infection. Journal of Infection. 2014;68(2):198-200. <https://doi.org/10.1016/j.jinf.2013.10.004> PMID:24140064
 13. Khoshnood S, Eslami G, Hashemi A, Bahramian A, Heidary M, Yousefi N, et al. Distribution of Aminoglycoside Resistance Genes Among *Acinetobacter baumannii* Strains Isolated From Burn Patients in Tehran, Iran. Archives of Pediatric Infectious Diseases. 2017;5(3). <https://doi.org/10.5812/pedinfect.57263>
 14. Xiong X, Bromley EH, Oelschlaeger P, Woolfson DN, Spencer J. Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface loops direct the activity of a Qnr protein from a Gram-negative bacterium. Nucleic Acids Research. 2011;39(9):3917-27. <https://doi.org/10.1093/nar/gkq1296> PMID:21227918 PMCid:PMC3089455
 15. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. The Lancet Infectious Diseases. 2006;6(10):629-40. [https://doi.org/10.1016/S1473-3099\(06\)70599-0](https://doi.org/10.1016/S1473-3099(06)70599-0)
 16. Yang HY, Nam YS, Lee HJ. Prevalence of plasmid-mediated quinolone resistance genes among ciprofloxacin-nonsusceptible *Escherichia coli* and *Klebsiella pneumoniae* isolated from blood cultures in Korea. Canadian Journal of Infectious Diseases and Medical Microbiology. 2014;25(3):163-9. <https://doi.org/10.1155/2014/329541> PMID:25285114 PMCid:PMC4173980
 17. Camp C, Tatum OL. A review of *Acinetobacter baumannii* as a highly successful pathogen in times of war. Laboratory Medicine. 2015;41(11):649-57. <https://doi.org/10.1309/LM90JNDDDDWR13RE>
 18. Leski TA, Bangura U, Jimmy DH, Ansumana R, Lizewski SE, Li RW, et al. Identification of blaOXA-51-like, blaOXA-58, blaDIM-1, and blaVIM carbapenemase genes in hospital Enterobacteriaceae isolates from Sierra Leone. Journal of Clinical Microbiology. 2013;51(7):2435-8. <https://doi.org/10.1128/JCM.00832-13> PMID:23658259 PMCid:PMC3697688
 19. Antunes L, Visca P, Towner KJ. *Acinetobacter baumannii*: evolution of a global pathogen. Pathogens and Disease. 2014;71(3):292-301. <https://doi.org/10.1111/2049-632X.12125> PMID:24376225
 20. Babapour E, Haddadi A, Mirnejad R, Angaji S-A, Amirmozafari N. Study of drug resistance and ompA gene existence in clinical *Acinetobacter baumannii* isolates. Iran J Med Microbiol 2017, 11(1): 30-38
 21. Zarrilli R, Pourmaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant *Acinetobacter baumannii* clonal lineages. International Journal of Antimicrobial Agents. 2013;41(1):11-9. <https://doi.org/10.1016/j.ijantimicag.2012.09.008> PMID:23127486
 22. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of *Acinetobacter* in the UK, and in vitro evaluation of tigecycline (GAR-936). Journal of Antimicrobial Chemotherapy. 2002;49(3):479-87. <https://doi.org/10.1093/jac/49.3.479> PMID:11864948
 23. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* from hospitalized patients in the United States, 1998 to 2001. Antimicrobial Agents and Chemotherapy. 2003;47(5):1681-8. <https://doi.org/10.1128/AAC.47.5.1681-1688.2003> PMID:12709340 PMCid:PMC153334
 24. Razavi Nikoo H, Ardebili A, Mardaneh J. Systematic review of antimicrobial resistance of clinical *Acinetobacter baumannii* isolates in Iran: an update. Microbial Drug Resistance. 2017;23(6):744-56. <https://doi.org/10.1089/mdr.2016.0118>
 25. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, et al. Analysis of antibiotic resistance genes in multidrug-resistant *Acinetobacter* sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrobial Agents and Chemotherapy. 2006;50(12):4114-23. <https://doi.org/10.1128/AAC.00778-06> PMID:17000742 PMCid:PMC1694013
 26. Chagas TPG, Oliveira TRT, Ribeiro SS, Aires CAM, Carvalho-Assef, APD'A, Asensi MD. Detection of plasmid-mediated Quinolone resistance genes (qnr) among *Acinetobacter baumannii* isolated from BRAZIL. XXVIII Congresso Brasileiro Microbiologia 2016. <https://www.researchgate.net/publication/318223832https://www.researchgate.net/publication/318223832>